pocenbrodib

Pocenbrodib is an orally bioavailable small molecule inhibitor targeting the bromodomain of the histone acetyltransferase paralogs CREB binding protein (CBP) and p300. By inhibiting these proteins—key transcriptional coactivators involved in gene expression and cancer progression—pocenbrodib disrupts histone acetylation and prevents coactivation of the androgen receptor (AR), including AR variants implicated in resistance to standard therapies. This mechanism may inhibit tumor cell proliferation in AR-positive cancers. Pocenbrodib is being developed primarily for metastatic castration-resistant prostate cancer (mCRPC), both as monotherapy and in combination with agents such as abiraterone acetate, olaparib, or 177Lu‑PSMA‑617. The drug is currently undergoing Phase 1b/2a clinical trials to assess safety and efficacy in patients who have progressed after prior anti-androgen therapy[2][3][5][6][7].

Other names

2304372-79-8(1R,3R)-3-[(7S)-2-[(R)-(5-Fluoro-2-methoxyphenyl)-hydroxymethyl]-6-methoxycarbonyl-7-methyl-8,9-dihydro-7H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid